Cholangiocarcinoma is the second most common primary liver cancer. Its incidence is low in
the Western world but is rising globally. Surgery, chemotherapy and radiation therapy have …

Reversible, spatial, and temporal regulation of metabolic reprogramming and epigenetic
homeostasis are prominent hallmarks of carcinogenesis. Cancer cells reprogram their …

IFN-γ, a soluble cytokine being produced by T lymphocytes, macrophages, mucosal
epithelial cells, or natural killer cells, is able to bind to the IFN-γ receptor (IFNγR) and in turn …

Intrahepatic cholangiocarcinoma (iCCA) exhibits extensive intratumoral heterogeneity and
an extremely high mortality rate. Here, we performed whole-exome sequencing, RNA …

Ten-eleven translocation (TET) family proteins (TETs), specifically, TET1, TET2 and TET3,
can modify DNA by oxidizing 5-methylcytosine (5mC) iteratively to yield 5 …

The mutant IDH1 inhibitor ivosidenib improves outcomes for patients with IDH1-mutated
cholangiocarcinoma, but resistance inevitably develops. Mechanisms of resistance and …

Biliary tract cancers are an uncommon set of gastrointestinal malignancies that are
associated with high morbidity and mortality rates. Most patients present with incurable …

Cholangiocarcinoma (CCA) is a rare malignancy that develops at any point along the biliary
tree. CCA has a poor prognosis, its clinical management remains challenging, and effective …

Abstract Isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) are the most frequently mutated
metabolic genes across human cancers. These hotspot gain‐of‐function mutations cause …

The incidence of cholangiocarcinoma (CCA) has been increasing over the past few years.
Although there are surgery, chemotherapy and other conventional treatment methods, the …